The English Countryside brings Innovation in Immuno-Oncology

This week we’re back to England, visiting a company in Winnersh, a countryside village not far from Reading and its famous university. There, Vernalis works to develop and commercialize therapies ranging from the common cough cold to the most recent advances in immuno-oncology.

Vernalis immuno oncology

Mission: Vernalis is a commercial stage pharma with products for cough cold, antibiotics and a migraine treatment. However, its most attractive assets are still under development. The company is running 6 programs in cancer with partners such as Servier or Novartis. Among its candidates, there’s an immuno-oncology drug, CPI-444, for renal cell carcinoma.

Comment: Vernalis counts with funds from “legendary biotech investor” Neil Woodford, who is surely pleased by the progress of the company, which just received a €2.8M ($3M) milestone payment from its collaborator Corvus Pharmaceuticals after the announcement of positive Phase I/Ib data on CPI-444. Interestingly, the adenosine A2A receptor antagonist was originally investigated as a treatment for Parkinson’s.

Images by Mubus7 / Shutterstock; Labiotech Map

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.